Liver Cirrhosis Pipeline Outlook Report 2024 (Updated)

DelveInsight's, "Liver Cirrhosis Pipeline Insight 2024" report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Liver Cirrhosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Liver Cirrhosis Pipeline Report
• DelveInsight's Liver Cirrhosis pipeline report depicts a robust space with 45+ active players working to develop 50+ pipeline therapies for Liver Cirrhosis treatment.
• The leading Liver Cirrhosis Companies includes CymaBay Therapeutics, Mirum Pharmaceuticals, Pharmicell Co., Ltd., Can-Fite BioPharma, Genfit, SHIONOGI & Co., COUR Pharmaceutical, Zydus Therapeutics Inc, Genkyotex SA, Gannex Pharma Co., Ltd., Novartis, HighTide Biopharma Pty Ltd, Chia Tai Tianqing Pharmaceutical Group Co.Ltd., GlaxoSmithKline, Ohara Pharmaceutical, Pliant Therapeutics, MYR Pharmaceuticals, Active Biotech, Future Medicine Co Ltd., Dr. Falk Pharma GmbH, Suzhou Zelgen Biopharmaceuticals, and others.
• Promising Liver Cirrhosis Pipeline Therapies includes IDN-6556, ADSCs, NGM282, Rifaximin SSD 40 mg IR tablet, Livercellgram, INT-747, Obeticholic Acid (OCA), and others.
• April 2024: Yale University announced a study of Phase 2 clinical trials for Empagliflozin 10 MG. A proof-of-concept placebo-controlled trial to explore the acute and 14-day effects of empagliflozin on natriuresis and total body water in patients with cirrhosis and ascites. We will additionally investigate its effect on neurohumoral activation, and renal hemodynamics.
• April 2024: Healthgen Biotechnology Cor. announced a study of Phase 3 clinical trials for OsrHSA. The goal of this clinical trial is to evaluate the efficacy of OsrHSA works to treat hypoalbuminemia in hepatic cirrhosis patients. It will also learn about the safety and immunogenicity of OsrHSA. The main question it aims to answer is whether OsrHSA is effective in elevating the serum albumin level of cirrhotic patients with hypoalbuminemia.

Request a sample and discover the recent advances in Liver Cirrhosis Treatment Drugs @ Liver Cirrhosis Pipeline Outlook Report- https://www.delveinsight.com/sample-request/liver-cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Liver Cirrhosis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Liver Cirrhosis NDA approvals (if any), and product development activities comprising the technology, Liver Cirrhosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Liver Cirrhosis Overview
Liver cirrhosis is a condition in which the liver is scarred and permanently damaged, and scar tissue replaces healthy liver tissue, preventing the liver from working normally. Cirrhosis is usually caused by long-term liver damage from conditions such as alcohol-associated liver disease, nonalcoholic fatty liver disease, chronic hepatitis C, and chronic hepatitis B. Symptoms of cirrhosis may not appear until the liver is badly damaged and can include fatigue, severe itchy skin, and swelling in the legs and abdomen. Doctors diagnose cirrhosis based on medical history, a physical exam, and the results of tests such as blood tests, imaging tests, and liver biopsy.

Find out more about Liver Cirrhosis Therapeutics Assessment @ Liver Cirrhosis Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/liver-cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Liver Cirrhosis Emerging Drugs Profile

• Elafibranor: Ipsen
Elafibranor (GFT-505) is under development for the treatment of colitis, non-alcoholic fatty liver disease, primary biliary cholangitis (PBC), and primary sclerosing cholangitis. The drug candidate is administered orally as a coated tablet. It acts by targeting peroxisome proliferator-activated receptor (PPAR) alpha and PPAR-beta / PPAR- delta. The drug candidate was under development for dyslipidemia, abdominal obesity, type 2 diabetes, Crohn's disease, insulin resistance and glucose intolerance, colitis and NAFLD/NASH-induced hepatocellular carcinoma (HCC). In December 2023, Ipsen and GENFIT announced that the US Food and Drug Administration (FDA) had accepted the New Drug Application (NDA) for investigational elafibranor.

• Volixibat: Mirum Pharmaceuticals
Volixibat is a minimally absorbed, orally administered investigational therapy designed to selectively inhibit ileal bile acid transporter (IBAT), a protein that is primarily responsible for recycling bile acids from the intestine to the liver. The company believes that volixibat may offer a novel approach in the treatment of rare liver diseases impacting both adults and children by blocking the recycling of bile acids, thereby reducing bile acids systemically. Volixibat is currently being studied in intrahepatic cholestasis of pregnancy, primary sclerosing cholangitis, and primary biliary cholangitis. Currently, the drug is in Phase II stage of its clinical trial.

• PVT201: Parvus Therapeutics
Parvus Therapeutics, a biopharmaceutical company developing PVT201 drug for the treatment of Primary Biliary Cholangitis. Currently, the drug is in preclinical stage of its development.

Liver Cirrhosis Therapeutics Assessment
There are approx. 45+ key Liver Cirrhosis companies which are developing the Liver Cirrhosis therapies. The Liver Cirrhosis companies which have their Liver Cirrhosis drug candidates in the most advanced stage, i.e. phase III include, Ipsen.

DelveInsight's Liver Cirrhosis pipeline report covers around 50+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Liver Cirrhosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Liver Cirrhosis Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Scope of the Liver Cirrhosis Pipeline Report
• Coverage- Global
• Liver Cirrhosis Companies- CymaBay Therapeutics, Mirum Pharmaceuticals, Pharmicell Co., Ltd., Can-Fite BioPharma, Genfit, SHIONOGI & Co., COUR Pharmaceutical, Zydus Therapeutics Inc, Genkyotex SA, Gannex Pharma Co., Ltd., Novartis, HighTide Biopharma Pty Ltd, Chia Tai Tianqing Pharmaceutical Group Co.Ltd., GlaxoSmithKline, Ohara Pharmaceutical, Pliant Therapeutics, MYR Pharmaceuticals, Active Biotech, Future Medicine Co Ltd., Dr. Falk Pharma GmbH, Suzhou Zelgen Biopharmaceuticals, and others.
• Liver Cirrhosis Pipeline Therapies- IDN-6556, ADSCs, NGM282, Rifaximin SSD 40 mg IR tablet, Livercellgram, INT-747, Obeticholic Acid (OCA), and others.
• Liver Cirrhosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Liver Cirrhosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Dive deep into rich insights for new drugs for Liver Cirrhosis Treatment, Visit @ Liver Cirrhosis Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/liver-cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Liver Cirrhosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Liver Cirrhosis - DelveInsight's Analytical Perspective
7. Late Stage Products (Registered)
8. Elafibranor: Ipsen
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Volixibat: Mirum Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Preclinical Stage Products
16. PVT201: Parvus Therapeutics
17. Inactive Products
18. Liver Cirrhosis - Collaborations Assessment- Licensing / Partnering / Funding
19. Liver Cirrhosis - Unmet Needs
20. Liver Cirrhosis - Market Drivers and Barriers
21. Appendix

For further information on the Liver Cirrhosis Pipeline therapeutics, reach out to Liver Cirrhosis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/liver-cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Links-

https://faceblox.mn.co/posts/54148443
https://edpt204w19.mn.co/posts/54148617
https://monewment.mn.co/posts/54148939
https://flexi-vegan.mn.co/posts/54149020
https://network-4526.mn.co/posts/54149059
https://redline-rp.mn.co/posts/54149156
https://sparklabsglobal.mn.co/posts/54149234
https://ajodance.mn.co/posts/54149267
https://datingwithprettygirls.mn.co/posts/54149313
https://dazed.mn.co/posts/54149356
https://moons.mn.co/posts/54149384
https://network-339477.mn.co/posts/54149409
https://match-ideas.mn.co/posts/54149766
https://ceo-codes.mn.co/posts/54149864
https://thinkinvestments.mn.co/members/23360451
https://spoder.mn.co/posts/54150026
https://network-64869.mn.co/posts/54150082
https://network-4448412.mn.co/posts/54150397
https://network-90620.mn.co/posts/54150432
https://network-16648.mn.co/posts/54150462
https://a-d-n.mn.co/posts/54150499
https://fcmcommunity.mn.co/posts/54280862
https://good-stewards.mn.co/posts/54280899
https://listening-works.mn.co/posts/54280919
https://network-20540.mn.co/posts/54280968
https://healing-communities-njde.mn.co/posts/54281001
https://runite.mn.co/posts/54281382
https://jasa-seo.mn.co/posts/54281443
https://louhangaround.mn.co/posts/54281497
https://onwayassociation.mn.co/posts/54281510
https://shaman-leaders.mn.co/posts/54281625
https://virtuous-rubies.mn.co/posts/54281637
https://extinct-networks.mn.co/posts/54281691
https://kingnobleblacksupremacy.mn.co/posts/54282200
https://ledpanellights.mn.co/posts/54282336
https://diy-vision.mn.co/posts/54282407
https://digimac-technologies.mn.co/posts/54282475
https://network-89593.mn.co/posts/54282548
https://tdcommunitynetworks.mn.co/posts/54282663
https://machine-parts-toolbox.mn.co/posts/54282718
https://wecanchat.mn.co/posts/exploring-the-dynamics-of-the-uveitis-market-insights-by-delveinsight
https://jointsnmotion-hub.mn.co/posts/54283557
https://artisthub.mn.co/posts/54283657
https://global-non-profit-network.mn.co/posts/54283837
https://jointsnmotion-hub.mn.co/posts/54283943
https://network-5674633.mn.co/posts/54284190
https://where-this-business-and-businesses.mn.co/posts/54284238
https://travelwithme.social/read-blog/34900

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:
https://www.delveinsight.com/report-store/medical-marijuana-market-insight
https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market

This release was published on openPR.